id	sid	tid	token	lemma	pos
dpc-5320	1	1	dermatology	dermatology	NOUN
dpc-5320	1	2	:	:	PUNCT
dpc-5320	1	3	practical	practical	ADJ
dpc-5320	1	4	and	and	CCONJ
dpc-5320	1	5	conceptual	conceptual	ADJ
dpc-5320	1	6	research	research	NOUN
dpc-5320	1	7	letter	letter	NOUN
dpc-5320	2	1	|	|	ADV
dpc-5320	2	2	dermatol	dermatol	ADJ
dpc-5320	2	3	pract	pract	NOUN
dpc-5320	2	4	concept	concept	NOUN
dpc-5320	2	5	.	.	PUNCT
dpc-5320	3	1	2025;15(3):5320	2025;15(3):5320	NUM
dpc-5320	3	2	1	1	NUM
dpc-5320	3	3	hepatotoxicity	hepatotoxicity	NOUN
dpc-5320	3	4	associated	associate	VERB
dpc-5320	3	5	with	with	ADP
dpc-5320	3	6	adalimumab	adalimumab	NOUN
dpc-5320	3	7	in	in	ADP
dpc-5320	3	8	hidradenitis	hidradenitis	PROPN
dpc-5320	3	9	suppurativa	suppurativa	PROPN
dpc-5320	3	10	:	:	PUNCT
dpc-5320	3	11	a	a	DET
dpc-5320	3	12	report	report	NOUN
dpc-5320	3	13	of	of	ADP
dpc-5320	3	14	two	two	NUM
dpc-5320	3	15	cases	case	NOUN
dpc-5320	3	16	of	of	ADP
dpc-5320	3	17	drug	drug	NOUN
dpc-5320	3	18	-	-	PUNCT
dpc-5320	3	19	induced	induce	VERB
dpc-5320	3	20	liver	liver	NOUN
dpc-5320	3	21	injury	injury	NOUN
dpc-5320	3	22	cristian	cristian	PROPN
dpc-5320	3	23	fernando	fernando	PROPN
dpc-5320	3	24	caballero	caballero	PROPN
dpc-5320	3	25	-	-	PUNCT
dpc-5320	3	26	linares1	linares1	PROPN
dpc-5320	3	27	,	,	PUNCT
dpc-5320	3	28	bianca	bianca	PROPN
dpc-5320	3	29	cei2	cei2	PROPN
dpc-5320	3	30	,	,	PUNCT
dpc-5320	3	31	fernando	fernando	NOUN
dpc-5320	3	32	alfageme1	alfageme1	NOUN
dpc-5320	3	33	1	1	NUM
dpc-5320	3	34	dermatology	dermatology	NOUN
dpc-5320	3	35	department	department	NOUN
dpc-5320	3	36	,	,	PUNCT
dpc-5320	3	37	hospital	hospital	NOUN
dpc-5320	3	38	universitario	universitario	PROPN
dpc-5320	3	39	puerta	puerta	PROPN
dpc-5320	3	40	de	de	PROPN
dpc-5320	3	41	hierro	hierro	PROPN
dpc-5320	3	42	majadahonda	majadahonda	PROPN
dpc-5320	3	43	,	,	PUNCT
dpc-5320	3	44	madrid	madrid	PROPN
dpc-5320	3	45	,	,	PUNCT
dpc-5320	3	46	spain	spain	PROPN
dpc-5320	3	47	2	2	NUM
dpc-5320	3	48	dermatology	dermatology	NOUN
dpc-5320	3	49	department	department	NOUN
dpc-5320	3	50	,	,	PUNCT
dpc-5320	3	51	university	university	PROPN
dpc-5320	3	52	of	of	ADP
dpc-5320	3	53	pisa	pisa	PROPN
dpc-5320	3	54	,	,	PUNCT
dpc-5320	3	55	italy	italy	PROPN
dpc-5320	3	56	key	key	ADJ
dpc-5320	3	57	words	word	NOUN
dpc-5320	3	58	:	:	PUNCT
dpc-5320	3	59	hidradenitis	hidradenitis	PROPN
dpc-5320	3	60	suppurativa	suppurativa	PROPN
dpc-5320	3	61	,	,	PUNCT
dpc-5320	3	62	adalimumab	adalimumab	NOUN
dpc-5320	3	63	,	,	PUNCT
dpc-5320	3	64	drug	drug	NOUN
dpc-5320	3	65	-	-	PUNCT
dpc-5320	3	66	induced	induce	VERB
dpc-5320	3	67	liver	liver	NOUN
dpc-5320	3	68	injury	injury	NOUN
dpc-5320	3	69	(	(	PUNCT
dpc-5320	3	70	dili	dili	PROPN
dpc-5320	3	71	)	)	PUNCT
dpc-5320	3	72	,	,	PUNCT
dpc-5320	3	73	hepatotoxicity	hepatotoxicity	NOUN
dpc-5320	3	74	,	,	PUNCT
dpc-5320	3	75	liver	liver	NOUN
dpc-5320	3	76	toxicity	toxicity	NOUN
dpc-5320	3	77	citation	citation	NOUN
dpc-5320	3	78	:	:	PUNCT
dpc-5320	3	79	caballero	caballero	ADJ
dpc-5320	3	80	-	-	PUNCT
dpc-5320	3	81	linares	linare	NOUN
dpc-5320	3	82	cf	cf	NOUN
dpc-5320	3	83	,	,	PUNCT
dpc-5320	3	84	bianca	bianca	PROPN
dpc-5320	3	85	c	c	PROPN
dpc-5320	3	86	,	,	PUNCT
dpc-5320	3	87	alfageme	alfageme	PROPN
dpc-5320	3	88	f.	f.	PROPN
dpc-5320	3	89	hepatotoxicity	hepatotoxicity	PROPN
dpc-5320	3	90	associated	associate	VERB
dpc-5320	3	91	with	with	ADP
dpc-5320	3	92	adalimumab	adalimumab	NOUN
dpc-5320	3	93	in	in	ADP
dpc-5320	3	94	hidradenitis	hidradenitis	PROPN
dpc-5320	3	95	suppurativa	suppurativa	PROPN
dpc-5320	3	96	:	:	PUNCT
dpc-5320	3	97	a	a	DET
dpc-5320	3	98	report	report	NOUN
dpc-5320	3	99	of	of	ADP
dpc-5320	3	100	two	two	NUM
dpc-5320	3	101	cases	case	NOUN
dpc-5320	3	102	of	of	ADP
dpc-5320	3	103	drug	drug	NOUN
dpc-5320	3	104	-	-	PUNCT
dpc-5320	3	105	induced	induce	VERB
dpc-5320	3	106	liver	liver	NOUN
dpc-5320	3	107	injury	injury	NOUN
dpc-5320	3	108	.	.	PUNCT
dpc-5320	4	1	dermatol	dermatol	NOUN
dpc-5320	4	2	pract	pract	PROPN
dpc-5320	4	3	concept	concept	NOUN
dpc-5320	4	4	.	.	PUNCT
dpc-5320	5	1	2025;15(3):5320	2025;15(3):5320	NOUN
dpc-5320	5	2	.	.	PUNCT
dpc-5320	6	1	doi	doi	PROPN
dpc-5320	6	2	:	:	PUNCT
dpc-5320	6	3	https://doi.org/10.5826/dpc.1503a5320	https://doi.org/10.5826/dpc.1503a5320	NOUN
dpc-5320	6	4	accepted	accept	VERB
dpc-5320	6	5	:	:	PUNCT
dpc-5320	6	6	january	january	PROPN
dpc-5320	6	7	27	27	NUM
dpc-5320	6	8	,	,	PUNCT
dpc-5320	6	9	2025	2025	NUM
dpc-5320	6	10	;	;	PUNCT
dpc-5320	6	11	published	publish	VERB
dpc-5320	6	12	:	:	PUNCT
dpc-5320	6	13	july	july	PROPN
dpc-5320	6	14	2025	2025	NUM
dpc-5320	6	15	copyright	copyright	NOUN
dpc-5320	6	16	:	:	PUNCT
dpc-5320	7	1	©	©	PROPN
dpc-5320	7	2	2025	2025	NUM
dpc-5320	7	3	caballero	caballero	NOUN
dpc-5320	7	4	-	-	PUNCT
dpc-5320	7	5	linares	linare	NOUN
dpc-5320	7	6	et	et	PROPN
dpc-5320	7	7	al	al	PROPN
dpc-5320	7	8	.	.	PUNCT
dpc-5320	8	1	this	this	PRON
dpc-5320	8	2	is	be	AUX
dpc-5320	8	3	an	an	DET
dpc-5320	8	4	open	open	ADJ
dpc-5320	8	5	-	-	PUNCT
dpc-5320	8	6	access	access	NOUN
dpc-5320	8	7	article	article	NOUN
dpc-5320	8	8	distributed	distribute	VERB
dpc-5320	8	9	under	under	ADP
dpc-5320	8	10	the	the	DET
dpc-5320	8	11	terms	term	NOUN
dpc-5320	8	12	of	of	ADP
dpc-5320	8	13	the	the	DET
dpc-5320	8	14	creative	creative	ADJ
dpc-5320	8	15	commons	common	NOUN
dpc-5320	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-5320	8	17	license	license	NOUN
dpc-5320	8	18	(	(	PUNCT
dpc-5320	8	19	by	by	ADP
dpc-5320	8	20	-	-	PUNCT
dpc-5320	8	21	nc-4.0	nc-4.0	NOUN
dpc-5320	8	22	)	)	PUNCT
dpc-5320	8	23	,	,	PUNCT
dpc-5320	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-5320	8	25	,	,	PUNCT
dpc-5320	8	26	which	which	PRON
dpc-5320	8	27	permits	permit	VERB
dpc-5320	8	28	unrestricted	unrestricted	ADJ
dpc-5320	8	29	noncommercial	noncommercial	ADJ
dpc-5320	8	30	use	use	NOUN
dpc-5320	8	31	,	,	PUNCT
dpc-5320	8	32	distribution	distribution	NOUN
dpc-5320	8	33	,	,	PUNCT
dpc-5320	8	34	and	and	CCONJ
dpc-5320	8	35	reproduction	reproduction	NOUN
dpc-5320	8	36	in	in	ADP
dpc-5320	8	37	any	any	DET
dpc-5320	8	38	medium	medium	NOUN
dpc-5320	8	39	,	,	PUNCT
dpc-5320	8	40	provided	provide	VERB
dpc-5320	8	41	the	the	DET
dpc-5320	8	42	original	original	ADJ
dpc-5320	8	43	authors	author	NOUN
dpc-5320	8	44	and	and	CCONJ
dpc-5320	8	45	source	source	NOUN
dpc-5320	8	46	are	be	AUX
dpc-5320	8	47	credited	credit	VERB
dpc-5320	8	48	.	.	PUNCT
dpc-5320	9	1	funding	funding	NOUN
dpc-5320	9	2	:	:	PUNCT
dpc-5320	9	3	none	none	NOUN
dpc-5320	9	4	.	.	PUNCT
dpc-5320	10	1	competing	compete	VERB
dpc-5320	10	2	interests	interest	NOUN
dpc-5320	10	3	:	:	PUNCT
dpc-5320	10	4	none	none	NOUN
dpc-5320	10	5	.	.	PUNCT
dpc-5320	11	1	authorship	authorship	NOUN
dpc-5320	11	2	:	:	PUNCT
dpc-5320	11	3	all	all	DET
dpc-5320	11	4	authors	author	NOUN
dpc-5320	11	5	have	have	AUX
dpc-5320	11	6	contributed	contribute	VERB
dpc-5320	11	7	significantly	significantly	ADV
dpc-5320	11	8	to	to	ADP
dpc-5320	11	9	this	this	DET
dpc-5320	11	10	publication	publication	NOUN
dpc-5320	11	11	.	.	PUNCT
dpc-5320	12	1	corresponding	correspond	VERB
dpc-5320	12	2	author	author	NOUN
dpc-5320	12	3	:	:	PUNCT
dpc-5320	12	4	cristian	cristian	PROPN
dpc-5320	12	5	fernando	fernando	PROPN
dpc-5320	12	6	caballero	caballero	PROPN
dpc-5320	12	7	-	-	PUNCT
dpc-5320	12	8	linares	linare	NOUN
dpc-5320	12	9	,	,	PUNCT
dpc-5320	12	10	md	md	PROPN
dpc-5320	12	11	,	,	PUNCT
dpc-5320	12	12	dermatology	dermatology	NOUN
dpc-5320	12	13	department	department	NOUN
dpc-5320	12	14	;	;	PUNCT
dpc-5320	12	15	hospital	hospital	NOUN
dpc-5320	12	16	universitario	universitario	PROPN
dpc-5320	12	17	puerta	puerta	PROPN
dpc-5320	12	18	de	de	PROPN
dpc-5320	12	19	hierro	hierro	PROPN
dpc-5320	12	20	majadahonda	majadahonda	PROPN
dpc-5320	12	21	;	;	PUNCT
dpc-5320	12	22	calle	calle	PROPN
dpc-5320	12	23	joaquín	joaquín	PROPN
dpc-5320	12	24	rodrigo	rodrigo	PROPN
dpc-5320	12	25	,	,	PUNCT
dpc-5320	12	26	1	1	NUM
dpc-5320	12	27	,	,	PUNCT
dpc-5320	12	28	28222	28222	NUM
dpc-5320	12	29	,	,	PUNCT
dpc-5320	12	30	majadahonda	majadahonda	NOUN
dpc-5320	12	31	,	,	PUNCT
dpc-5320	12	32	madrid	madrid	PROPN
dpc-5320	12	33	,	,	PUNCT
dpc-5320	12	34	spain	spain	PROPN
dpc-5320	12	35	.	.	PUNCT
dpc-5320	13	1	orcid	orcid	PROPN
dpc-5320	13	2	:	:	PUNCT
dpc-5320	13	3	0009	0009	NUM
dpc-5320	13	4	-	-	SYM
dpc-5320	13	5	0005	0005	NUM
dpc-5320	13	6	-	-	PUNCT
dpc-5320	13	7	5652	5652	NUM
dpc-5320	13	8	-	-	SYM
dpc-5320	13	9	7754	7754	NUM
dpc-5320	13	10	.	.	PUNCT
dpc-5320	14	1	e	e	X
dpc-5320	14	2	-	-	NOUN
dpc-5320	14	3	mail	mail	NOUN
dpc-5320	14	4	address	address	NOUN
dpc-5320	14	5	:	:	PUNCT
dpc-5320	14	6	cristianfernando.caballero@salud.madrid.org	cristianfernando.caballero@salud.madrid.org	ADJ
dpc-5320	14	7	.	.	PUNCT
dpc-5320	14	8	introduction	introduction	NOUN
dpc-5320	14	9	adalimumab	adalimumab	PROPN
dpc-5320	14	10	,	,	PUNCT
dpc-5320	14	11	a	a	DET
dpc-5320	14	12	tnf	tnf	PROPN
dpc-5320	14	13	-	-	PUNCT
dpc-5320	14	14	α	α	NOUN
dpc-5320	14	15	inhibitor	inhibitor	NOUN
dpc-5320	14	16	,	,	PUNCT
dpc-5320	14	17	is	be	AUX
dpc-5320	14	18	widely	widely	ADV
dpc-5320	14	19	used	use	VERB
dpc-5320	14	20	in	in	ADP
dpc-5320	14	21	hidradenitis	hidradenitis	PROPN
dpc-5320	14	22	suppurativa	suppurativa	PROPN
dpc-5320	14	23	(	(	PUNCT
dpc-5320	14	24	hs	hs	PROPN
dpc-5320	14	25	)	)	PUNCT
dpc-5320	14	26	.	.	PUNCT
dpc-5320	15	1	while	while	SCONJ
dpc-5320	15	2	generally	generally	ADV
dpc-5320	15	3	considered	consider	VERB
dpc-5320	15	4	safe	safe	ADJ
dpc-5320	15	5	,	,	PUNCT
dpc-5320	15	6	hepatotoxicity	hepatotoxicity	NOUN
dpc-5320	15	7	has	have	AUX
dpc-5320	15	8	been	be	AUX
dpc-5320	15	9	documented	document	VERB
dpc-5320	15	10	as	as	ADP
dpc-5320	15	11	a	a	DET
dpc-5320	15	12	potential	potential	ADJ
dpc-5320	15	13	adverse	adverse	ADJ
dpc-5320	15	14	effect	effect	NOUN
dpc-5320	15	15	.	.	PUNCT
dpc-5320	16	1	we	we	PRON
dpc-5320	16	2	present	present	VERB
dpc-5320	16	3	two	two	NUM
dpc-5320	16	4	cases	case	NOUN
dpc-5320	16	5	of	of	ADP
dpc-5320	16	6	drug	drug	NOUN
dpc-5320	16	7	-	-	PUNCT
dpc-5320	16	8	induced	induce	VERB
dpc-5320	16	9	liver	liver	NOUN
dpc-5320	16	10	injury	injury	NOUN
dpc-5320	16	11	(	(	PUNCT
dpc-5320	16	12	dili	dili	NOUN
dpc-5320	16	13	)	)	PUNCT
dpc-5320	16	14	associated	associate	VERB
dpc-5320	16	15	with	with	ADP
dpc-5320	16	16	adalimumab	adalimumab	NOUN
dpc-5320	16	17	in	in	ADP
dpc-5320	16	18	patients	patient	NOUN
dpc-5320	16	19	with	with	ADP
dpc-5320	16	20	hs	hs	PROPN
dpc-5320	16	21	,	,	PUNCT
dpc-5320	16	22	highlighting	highlight	VERB
dpc-5320	16	23	the	the	DET
dpc-5320	16	24	variability	variability	NOUN
dpc-5320	16	25	in	in	ADP
dpc-5320	16	26	onset	onset	NOUN
dpc-5320	16	27	and	and	CCONJ
dpc-5320	16	28	severity	severity	NOUN
dpc-5320	16	29	of	of	ADP
dpc-5320	16	30	hepatic	hepatic	ADJ
dpc-5320	16	31	damage	damage	NOUN
dpc-5320	16	32	.	.	PUNCT
dpc-5320	17	1	case	case	NOUN
dpc-5320	17	2	presentation	presentation	NOUN
dpc-5320	17	3	the	the	DET
dpc-5320	17	4	first	first	ADJ
dpc-5320	17	5	case	case	NOUN
dpc-5320	17	6	involves	involve	VERB
dpc-5320	17	7	a	a	DET
dpc-5320	17	8	47	47	NUM
dpc-5320	17	9	-	-	PUNCT
dpc-5320	17	10	year	year	NOUN
dpc-5320	17	11	-	-	PUNCT
dpc-5320	17	12	old	old	ADJ
dpc-5320	17	13	female	female	NOUN
dpc-5320	17	14	diagnosed	diagnose	VERB
dpc-5320	17	15	with	with	ADP
dpc-5320	17	16	hs	hs	PROPN
dpc-5320	17	17	hurley	hurley	PROPN
dpc-5320	17	18	iii	iii	PROPN
dpc-5320	17	19	in	in	ADP
dpc-5320	17	20	2019	2019	NUM
dpc-5320	17	21	,	,	PUNCT
dpc-5320	17	22	with	with	ADP
dpc-5320	17	23	a	a	DET
dpc-5320	17	24	medical	medical	ADJ
dpc-5320	17	25	history	history	NOUN
dpc-5320	17	26	of	of	ADP
dpc-5320	17	27	endometriosis	endometriosis	NOUN
dpc-5320	17	28	managed	manage	VERB
dpc-5320	17	29	with	with	ADP
dpc-5320	17	30	oral	oral	ADJ
dpc-5320	17	31	contraceptives	contraceptive	NOUN
dpc-5320	17	32	,	,	PUNCT
dpc-5320	17	33	no	no	DET
dpc-5320	17	34	known	know	VERB
dpc-5320	17	35	drug	drug	NOUN
dpc-5320	17	36	allergies	allergy	NOUN
dpc-5320	17	37	,	,	PUNCT
dpc-5320	17	38	no	no	DET
dpc-5320	17	39	hypertension	hypertension	NOUN
dpc-5320	17	40	,	,	PUNCT
dpc-5320	17	41	diabetes	diabetes	NOUN
dpc-5320	17	42	,	,	PUNCT
dpc-5320	17	43	or	or	CCONJ
dpc-5320	17	44	dyslipidemia	dyslipidemia	NOUN
dpc-5320	17	45	,	,	PUNCT
dpc-5320	17	46	and	and	CCONJ
dpc-5320	17	47	no	no	DET
dpc-5320	17	48	personal	personal	ADJ
dpc-5320	17	49	or	or	CCONJ
dpc-5320	17	50	family	family	NOUN
dpc-5320	17	51	history	history	NOUN
dpc-5320	17	52	of	of	ADP
dpc-5320	17	53	liver	liver	NOUN
dpc-5320	17	54	disease	disease	NOUN
dpc-5320	17	55	.	.	PUNCT
dpc-5320	18	1	she	she	PRON
dpc-5320	18	2	was	be	AUX
dpc-5320	18	3	initially	initially	ADV
dpc-5320	18	4	treated	treat	VERB
dpc-5320	18	5	with	with	ADP
dpc-5320	18	6	rifampicin	rifampicin	VERB
dpc-5320	18	7	and	and	CCONJ
dpc-5320	18	8	clindamycin	clindamycin	NOUN
dpc-5320	18	9	for	for	ADP
dpc-5320	18	10	two	two	NUM
dpc-5320	18	11	months	month	NOUN
dpc-5320	18	12	while	while	SCONJ
dpc-5320	18	13	undergoing	undergo	VERB
dpc-5320	18	14	pre	pre	ADJ
dpc-5320	18	15	-	-	ADJ
dpc-5320	18	16	biological	biological	ADJ
dpc-5320	18	17	screening	screening	NOUN
dpc-5320	18	18	.	.	PUNCT
dpc-5320	19	1	subsequently	subsequently	ADV
dpc-5320	19	2	,	,	PUNCT
dpc-5320	19	3	she	she	PRON
dpc-5320	19	4	started	start	VERB
dpc-5320	19	5	adalimumab	adalimumab	NOUN
dpc-5320	19	6	80	80	NUM
dpc-5320	19	7	mg	mg	NOUN
dpc-5320	19	8	every	every	DET
dpc-5320	19	9	two	two	NUM
dpc-5320	19	10	weeks	week	NOUN
dpc-5320	19	11	.	.	PUNCT
dpc-5320	20	1	in	in	ADP
dpc-5320	20	2	2021	2021	NUM
dpc-5320	20	3	,	,	PUNCT
dpc-5320	20	4	her	her	PRON
dpc-5320	20	5	therapy	therapy	NOUN
dpc-5320	20	6	was	be	AUX
dpc-5320	20	7	switched	switch	VERB
dpc-5320	20	8	to	to	ADP
dpc-5320	20	9	a	a	DET
dpc-5320	20	10	biosimilar	biosimilar	NOUN
dpc-5320	20	11	at	at	ADP
dpc-5320	20	12	the	the	DET
dpc-5320	20	13	same	same	ADJ
dpc-5320	20	14	dosage	dosage	NOUN
dpc-5320	20	15	.	.	PUNCT
dpc-5320	21	1	in	in	ADP
dpc-5320	21	2	july	july	PROPN
dpc-5320	21	3	2024	2024	NUM
dpc-5320	21	4	,	,	PUNCT
dpc-5320	21	5	after	after	ADP
dpc-5320	21	6	more	more	ADJ
dpc-5320	21	7	than	than	ADP
dpc-5320	21	8	two	two	NUM
dpc-5320	21	9	years	year	NOUN
dpc-5320	21	10	of	of	ADP
dpc-5320	21	11	treatment	treatment	NOUN
dpc-5320	21	12	,	,	PUNCT
dpc-5320	21	13	she	she	PRON
dpc-5320	21	14	developed	develop	VERB
dpc-5320	21	15	right	right	ADJ
dpc-5320	21	16	upper	upper	ADJ
dpc-5320	21	17	quadrant	quadrant	NOUN
dpc-5320	21	18	discomfort	discomfort	NOUN
dpc-5320	21	19	with	with	ADP
dpc-5320	21	20	transaminases	transaminase	NOUN
dpc-5320	21	21	elevated	elevate	VERB
dpc-5320	21	22	fivefold	fivefold	ADV
dpc-5320	21	23	.	.	PUNCT
dpc-5320	22	1	liver	liver	NOUN
dpc-5320	22	2	elastography	elastography	NOUN
dpc-5320	22	3	,	,	PUNCT
dpc-5320	22	4	previously	previously	ADV
dpc-5320	22	5	normal	normal	ADJ
dpc-5320	22	6	,	,	PUNCT
dpc-5320	22	7	revealed	reveal	VERB
dpc-5320	22	8	severe	severe	ADJ
dpc-5320	22	9	steatosis	steatosis	NOUN
dpc-5320	22	10	;	;	PUNCT
dpc-5320	22	11	antinuclear	antinuclear	ADJ
dpc-5320	22	12	and	and	CCONJ
dpc-5320	22	13	liver	liver	NOUN
dpc-5320	22	14	-	-	PUNCT
dpc-5320	22	15	specific	specific	ADJ
dpc-5320	22	16	antibodies	antibody	NOUN
dpc-5320	22	17	were	be	AUX
dpc-5320	22	18	negative	negative	ADJ
dpc-5320	22	19	.	.	PUNCT
dpc-5320	23	1	adalimumab	adalimumab	NOUN
dpc-5320	23	2	was	be	AUX
dpc-5320	23	3	discontinued	discontinue	VERB
dpc-5320	23	4	,	,	PUNCT
dpc-5320	23	5	and	and	CCONJ
dpc-5320	23	6	she	she	PRON
dpc-5320	23	7	received	receive	VERB
dpc-5320	23	8	a	a	DET
dpc-5320	23	9	tapering	taper	VERB
dpc-5320	23	10	course	course	NOUN
dpc-5320	23	11	of	of	ADP
dpc-5320	23	12	oral	oral	ADJ
dpc-5320	23	13	corticosteroids	corticosteroid	NOUN
dpc-5320	23	14	,	,	PUNCT
dpc-5320	23	15	with	with	ADP
dpc-5320	23	16	progressive	progressive	ADJ
dpc-5320	23	17	improvement	improvement	NOUN
dpc-5320	23	18	in	in	ADP
dpc-5320	23	19	liver	liver	NOUN
dpc-5320	23	20	enzymes	enzyme	NOUN
dpc-5320	23	21	.	.	PUNCT
dpc-5320	24	1	the	the	DET
dpc-5320	24	2	second	second	ADJ
dpc-5320	24	3	case	case	NOUN
dpc-5320	24	4	describes	describe	VERB
dpc-5320	24	5	a	a	DET
dpc-5320	24	6	56	56	NUM
dpc-5320	24	7	-	-	PUNCT
dpc-5320	24	8	year	year	NOUN
dpc-5320	24	9	-	-	PUNCT
dpc-5320	24	10	old	old	ADJ
dpc-5320	24	11	female	female	NOUN
dpc-5320	24	12	,	,	PUNCT
dpc-5320	24	13	smoker	smoker	NOUN
dpc-5320	24	14	(	(	PUNCT
dpc-5320	24	15	eight	eight	NUM
dpc-5320	24	16	cigarettes	cigarette	NOUN
dpc-5320	24	17	/	/	SYM
dpc-5320	24	18	day	day	NOUN
dpc-5320	24	19	)	)	PUNCT
dpc-5320	24	20	,	,	PUNCT
dpc-5320	24	21	with	with	ADP
dpc-5320	24	22	a	a	DET
dpc-5320	24	23	history	history	NOUN
dpc-5320	24	24	of	of	ADP
dpc-5320	24	25	anxiety	anxiety	NOUN
dpc-5320	24	26	managed	manage	VERB
dpc-5320	24	27	intermittenly	intermittenly	ADV
dpc-5320	24	28	with	with	ADP
dpc-5320	24	29	lorazepam	lorazepam	NOUN
dpc-5320	24	30	,	,	PUNCT
dpc-5320	24	31	no	no	DET
dpc-5320	24	32	drug	drug	NOUN
dpc-5320	24	33	allergies	allergy	NOUN
dpc-5320	24	34	or	or	CCONJ
dpc-5320	24	35	chronic	chronic	ADJ
dpc-5320	24	36	comorbidities	comorbiditie	NOUN
dpc-5320	24	37	,	,	PUNCT
dpc-5320	24	38	and	and	CCONJ
dpc-5320	24	39	no	no	DET
dpc-5320	24	40	personal	personal	ADJ
dpc-5320	24	41	or	or	CCONJ
dpc-5320	24	42	family	family	NOUN
dpc-5320	24	43	history	history	NOUN
dpc-5320	24	44	of	of	ADP
dpc-5320	24	45	liver	liver	NOUN
dpc-5320	24	46	disease	disease	NOUN
dpc-5320	24	47	.	.	PUNCT
dpc-5320	25	1	diagnosed	diagnose	VERB
dpc-5320	25	2	with	with	ADP
dpc-5320	25	3	hs	hs	PROPN
dpc-5320	25	4	hurley	hurley	PROPN
dpc-5320	25	5	iii	iii	PROPN
dpc-5320	25	6	in	in	ADP
dpc-5320	25	7	february	february	PROPN
dpc-5320	25	8	2022	2022	NUM
dpc-5320	25	9	,	,	PUNCT
dpc-5320	25	10	she	she	PRON
dpc-5320	25	11	initially	initially	ADV
dpc-5320	25	12	received	receive	VERB
dpc-5320	25	13	clindamycin	clindamycin	NOUN
dpc-5320	25	14	for	for	ADP
dpc-5320	25	15	one	one	NUM
dpc-5320	25	16	month	month	NOUN
dpc-5320	25	17	during	during	ADP
dpc-5320	25	18	her	her	PRON
dpc-5320	25	19	pre	pre	ADJ
dpc-5320	25	20	-	-	ADJ
dpc-5320	25	21	biological	biological	ADJ
dpc-5320	25	22	screening	screening	NOUN
dpc-5320	25	23	.	.	PUNCT
dpc-5320	26	1	then	then	ADV
dpc-5320	26	2	,	,	PUNCT
dpc-5320	26	3	adalimumab	adalimumab	NOUN
dpc-5320	26	4	was	be	AUX
dpc-5320	26	5	initiated	initiate	VERB
dpc-5320	26	6	in	in	ADP
dpc-5320	26	7	april	april	PROPN
dpc-5320	26	8	2022	2022	NUM
dpc-5320	26	9	2	2	NUM
dpc-5320	26	10	research	research	NOUN
dpc-5320	26	11	letter	letter	NOUN
dpc-5320	26	12	|	|	ADV
dpc-5320	26	13	dermatol	dermatol	ADJ
dpc-5320	26	14	pract	pract	NOUN
dpc-5320	26	15	concept	concept	NOUN
dpc-5320	26	16	.	.	PUNCT
dpc-5320	27	1	2025;15(3):5320	2025;15(3):5320	NUM
dpc-5320	27	2	with	with	ADP
dpc-5320	27	3	an	an	DET
dpc-5320	27	4	induction	induction	NOUN
dpc-5320	27	5	dose	dose	NOUN
dpc-5320	27	6	of	of	ADP
dpc-5320	27	7	160	160	NUM
dpc-5320	27	8	mg	mg	NOUN
dpc-5320	27	9	.	.	PUNCT
dpc-5320	28	1	within	within	ADP
dpc-5320	28	2	just	just	ADV
dpc-5320	28	3	three	three	NUM
dpc-5320	28	4	days	day	NOUN
dpc-5320	28	5	of	of	ADP
dpc-5320	28	6	this	this	DET
dpc-5320	28	7	first	first	ADJ
dpc-5320	28	8	and	and	CCONJ
dpc-5320	28	9	only	only	ADV
dpc-5320	28	10	dose	dose	PROPN
dpc-5320	28	11	,	,	PUNCT
dpc-5320	28	12	she	she	PRON
dpc-5320	28	13	developed	develop	VERB
dpc-5320	28	14	severe	severe	ADJ
dpc-5320	28	15	epigastric	epigastric	NOUN
dpc-5320	28	16	pain	pain	NOUN
dpc-5320	28	17	.	.	PUNCT
dpc-5320	29	1	laboratory	laboratory	NOUN
dpc-5320	29	2	tests	test	NOUN
dpc-5320	29	3	revealed	reveal	VERB
dpc-5320	29	4	elevated	elevate	VERB
dpc-5320	29	5	alt	alt	ADJ
dpc-5320	29	6	(	(	PUNCT
dpc-5320	29	7	1595	1595	NUM
dpc-5320	29	8	u	u	PROPN
dpc-5320	29	9	/	/	SYM
dpc-5320	29	10	l	l	NOUN
dpc-5320	29	11	)	)	PUNCT
dpc-5320	29	12	,	,	PUNCT
dpc-5320	29	13	ast	ast	INTJ
dpc-5320	29	14	(	(	PUNCT
dpc-5320	29	15	587	587	NUM
dpc-5320	29	16	u	u	NOUN
dpc-5320	29	17	/	/	SYM
dpc-5320	29	18	l	l	NOUN
dpc-5320	29	19	)	)	PUNCT
dpc-5320	29	20	,	,	PUNCT
dpc-5320	29	21	and	and	CCONJ
dpc-5320	29	22	ggt	ggt	NOUN
dpc-5320	29	23	(	(	PUNCT
dpc-5320	29	24	556	556	NUM
dpc-5320	29	25	u	u	NOUN
dpc-5320	29	26	/	/	SYM
dpc-5320	29	27	l	l	NOUN
dpc-5320	29	28	)	)	PUNCT
dpc-5320	29	29	.	.	PUNCT
dpc-5320	30	1	liver	liver	NOUN
dpc-5320	30	2	elastography	elastography	NOUN
dpc-5320	30	3	was	be	AUX
dpc-5320	30	4	normal	normal	ADJ
dpc-5320	30	5	;	;	PUNCT
dpc-5320	30	6	antinuclear	antinuclear	ADJ
dpc-5320	30	7	and	and	CCONJ
dpc-5320	30	8	liver	liver	NOUN
dpc-5320	30	9	-	-	PUNCT
dpc-5320	30	10	related	relate	VERB
dpc-5320	30	11	antibodies	antibody	NOUN
dpc-5320	30	12	were	be	AUX
dpc-5320	30	13	negative	negative	ADJ
dpc-5320	30	14	.	.	PUNCT
dpc-5320	31	1	adalimumab	adalimumab	NOUN
dpc-5320	31	2	was	be	AUX
dpc-5320	31	3	immediately	immediately	ADV
dpc-5320	31	4	discontinued	discontinue	VERB
dpc-5320	31	5	,	,	PUNCT
dpc-5320	31	6	and	and	CCONJ
dpc-5320	31	7	liver	liver	NOUN
dpc-5320	31	8	enzymes	enzyme	NOUN
dpc-5320	31	9	gradually	gradually	ADV
dpc-5320	31	10	normalized	normalize	VERB
dpc-5320	31	11	during	during	ADP
dpc-5320	31	12	follow	follow	NOUN
dpc-5320	31	13	-	-	PUNCT
dpc-5320	31	14	up	up	NOUN
dpc-5320	31	15	.	.	PUNCT
dpc-5320	32	1	the	the	DET
dpc-5320	32	2	final	final	ADJ
dpc-5320	32	3	diagnosis	diagnosis	NOUN
dpc-5320	32	4	was	be	AUX
dpc-5320	32	5	dili	dili	PROPN
dpc-5320	32	6	,	,	PUNCT
dpc-5320	32	7	attributed	attribute	VERB
dpc-5320	32	8	to	to	ADP
dpc-5320	32	9	recent	recent	ADJ
dpc-5320	32	10	adalimumab	adalimumab	NOUN
dpc-5320	32	11	initiation	initiation	NOUN
dpc-5320	32	12	.	.	PUNCT
dpc-5320	33	1	hepatotoxicity	hepatotoxicity	NOUN
dpc-5320	33	2	occurred	occur	VERB
dpc-5320	33	3	at	at	ADP
dpc-5320	33	4	different	different	ADJ
dpc-5320	33	5	stagesdelayed	stagesdelaye	VERB
dpc-5320	33	6	in	in	ADP
dpc-5320	33	7	the	the	DET
dpc-5320	33	8	first	first	ADJ
dpc-5320	33	9	case	case	NOUN
dpc-5320	33	10	and	and	CCONJ
dpc-5320	33	11	acute	acute	NOUN
dpc-5320	33	12	in	in	ADP
dpc-5320	33	13	the	the	DET
dpc-5320	33	14	secondhighlighting	secondhighlighting	NOUN
dpc-5320	33	15	the	the	DET
dpc-5320	33	16	unpredictable	unpredictable	ADJ
dpc-5320	33	17	latency	latency	NOUN
dpc-5320	33	18	of	of	ADP
dpc-5320	33	19	dili	dili	PROPN
dpc-5320	33	20	.	.	PUNCT
dpc-5320	34	1	as	as	SCONJ
dpc-5320	34	2	noted	note	VERB
dpc-5320	34	3	by	by	ADP
dpc-5320	34	4	frider	frider	PROPN
dpc-5320	34	5	et	et	PROPN
dpc-5320	34	6	al	al	PROPN
dpc-5320	34	7	.	.	PUNCT
dpc-5320	35	1	[	[	X
dpc-5320	35	2	1	1	NUM
dpc-5320	35	3	]	]	PUNCT
dpc-5320	35	4	,	,	PUNCT
dpc-5320	35	5	adalimumab	adalimumab	NOUN
dpc-5320	35	6	-	-	PUNCT
dpc-5320	35	7	related	relate	VERB
dpc-5320	35	8	liver	liver	NOUN
dpc-5320	35	9	injury	injury	NOUN
dpc-5320	35	10	is	be	AUX
dpc-5320	35	11	often	often	ADV
dpc-5320	35	12	idiosyncratic	idiosyncratic	ADJ
dpc-5320	35	13	,	,	PUNCT
dpc-5320	35	14	likely	likely	ADV
dpc-5320	35	15	driven	drive	VERB
dpc-5320	35	16	by	by	ADP
dpc-5320	35	17	an	an	DET
dpc-5320	35	18	abnormal	abnormal	ADJ
dpc-5320	35	19	immune	immune	ADJ
dpc-5320	35	20	response	response	NOUN
dpc-5320	35	21	rather	rather	ADV
dpc-5320	35	22	than	than	ADP
dpc-5320	35	23	a	a	DET
dpc-5320	35	24	direct	direct	ADJ
dpc-5320	35	25	dose	dose	NOUN
dpc-5320	35	26	-	-	PUNCT
dpc-5320	35	27	dependent	dependent	ADJ
dpc-5320	35	28	toxicity	toxicity	NOUN
dpc-5320	35	29	.	.	PUNCT
dpc-5320	36	1	elevated	elevated	ADJ
dpc-5320	36	2	transaminases	transaminase	NOUN
dpc-5320	36	3	were	be	AUX
dpc-5320	36	4	the	the	DET
dpc-5320	36	5	main	main	ADJ
dpc-5320	36	6	laboratory	laboratory	NOUN
dpc-5320	36	7	finding	finding	NOUN
dpc-5320	36	8	in	in	ADP
dpc-5320	36	9	both	both	DET
dpc-5320	36	10	cases	case	NOUN
dpc-5320	36	11	,	,	PUNCT
dpc-5320	36	12	reflecting	reflect	VERB
dpc-5320	36	13	the	the	DET
dpc-5320	36	14	degree	degree	NOUN
dpc-5320	36	15	of	of	ADP
dpc-5320	36	16	hepatocellular	hepatocellular	ADJ
dpc-5320	36	17	injury	injury	NOUN
dpc-5320	36	18	.	.	PUNCT
dpc-5320	37	1	in	in	ADP
dpc-5320	37	2	the	the	DET
dpc-5320	37	3	second	second	ADJ
dpc-5320	37	4	case	case	NOUN
dpc-5320	37	5	,	,	PUNCT
dpc-5320	37	6	the	the	DET
dpc-5320	37	7	rapid	rapid	ADJ
dpc-5320	37	8	onset	onset	NOUN
dpc-5320	37	9	with	with	ADP
dpc-5320	37	10	transaminase	transaminase	NOUN
dpc-5320	37	11	elevation	elevation	NOUN
dpc-5320	37	12	within	within	ADP
dpc-5320	37	13	days	day	NOUN
dpc-5320	37	14	of	of	ADP
dpc-5320	37	15	starting	start	VERB
dpc-5320	37	16	treatment	treatment	NOUN
dpc-5320	37	17	suggests	suggest	VERB
dpc-5320	37	18	a	a	DET
dpc-5320	37	19	more	more	ADV
dpc-5320	37	20	severe	severe	ADJ
dpc-5320	37	21	inflammatory	inflammatory	ADJ
dpc-5320	37	22	response	response	NOUN
dpc-5320	37	23	,	,	PUNCT
dpc-5320	37	24	indicating	indicate	VERB
dpc-5320	37	25	acute	acute	ADJ
dpc-5320	37	26	liver	liver	NOUN
dpc-5320	37	27	damage	damage	NOUN
dpc-5320	37	28	.	.	PUNCT
dpc-5320	38	1	the	the	DET
dpc-5320	38	2	underlying	underlying	ADJ
dpc-5320	38	3	mechanism	mechanism	NOUN
dpc-5320	38	4	of	of	ADP
dpc-5320	38	5	adalimumab	adalimumab	NOUN
dpc-5320	38	6	-	-	PUNCT
dpc-5320	38	7	induced	induce	VERB
dpc-5320	38	8	hepatotoxicity	hepatotoxicity	NOUN
dpc-5320	38	9	is	be	AUX
dpc-5320	38	10	not	not	PART
dpc-5320	38	11	entirely	entirely	ADV
dpc-5320	38	12	understood	understand	VERB
dpc-5320	38	13	.	.	PUNCT
dpc-5320	39	1	it	it	PRON
dpc-5320	39	2	may	may	AUX
dpc-5320	39	3	involve	involve	VERB
dpc-5320	39	4	aberrant	aberrant	ADJ
dpc-5320	39	5	immune	immune	ADJ
dpc-5320	39	6	activation	activation	NOUN
dpc-5320	39	7	due	due	ADP
dpc-5320	39	8	to	to	ADP
dpc-5320	39	9	tnf	tnf	PROPN
dpc-5320	39	10	-	-	PUNCT
dpc-5320	39	11	α	α	NOUN
dpc-5320	39	12	blockade	blockade	NOUN
dpc-5320	39	13	,	,	PUNCT
dpc-5320	39	14	potentially	potentially	ADV
dpc-5320	39	15	resulting	result	VERB
dpc-5320	39	16	in	in	ADP
dpc-5320	39	17	eosinophilic	eosinophilic	ADJ
dpc-5320	39	18	infiltration	infiltration	NOUN
dpc-5320	39	19	and	and	CCONJ
dpc-5320	39	20	hepatic	hepatic	ADJ
dpc-5320	39	21	inflammation	inflammation	NOUN
dpc-5320	39	22	,	,	PUNCT
dpc-5320	39	23	as	as	SCONJ
dpc-5320	39	24	seen	see	VERB
dpc-5320	39	25	in	in	ADP
dpc-5320	39	26	liver	liver	NOUN
dpc-5320	39	27	biopsies	biopsy	NOUN
dpc-5320	39	28	from	from	ADP
dpc-5320	39	29	affected	affected	ADJ
dpc-5320	39	30	patients	patient	NOUN
dpc-5320	39	31	[	[	X
dpc-5320	39	32	2	2	NUM
dpc-5320	39	33	]	]	PUNCT
dpc-5320	39	34	.	.	PUNCT
dpc-5320	40	1	the	the	DET
dpc-5320	40	2	resolution	resolution	NOUN
dpc-5320	40	3	of	of	ADP
dpc-5320	40	4	liver	liver	NOUN
dpc-5320	40	5	enzyme	enzyme	NOUN
dpc-5320	40	6	abnormalities	abnormality	NOUN
dpc-5320	40	7	following	follow	VERB
dpc-5320	40	8	drug	drug	NOUN
dpc-5320	40	9	discontinuation	discontinuation	NOUN
dpc-5320	40	10	,	,	PUNCT
dpc-5320	40	11	as	as	SCONJ
dpc-5320	40	12	observed	observe	VERB
dpc-5320	40	13	in	in	ADP
dpc-5320	40	14	our	our	PRON
dpc-5320	40	15	patients	patient	NOUN
dpc-5320	40	16	,	,	PUNCT
dpc-5320	40	17	supports	support	VERB
dpc-5320	40	18	the	the	DET
dpc-5320	40	19	idea	idea	NOUN
dpc-5320	40	20	that	that	PRON
dpc-5320	40	21	prompt	prompt	ADJ
dpc-5320	40	22	cessation	cessation	NOUN
dpc-5320	40	23	of	of	ADP
dpc-5320	40	24	therapy	therapy	NOUN
dpc-5320	40	25	is	be	AUX
dpc-5320	40	26	crucial	crucial	ADJ
dpc-5320	40	27	to	to	ADP
dpc-5320	40	28	preventing	prevent	VERB
dpc-5320	40	29	severe	severe	ADJ
dpc-5320	40	30	liver	liver	NOUN
dpc-5320	40	31	damage	damage	NOUN
dpc-5320	40	32	[	[	X
dpc-5320	40	33	3	3	NUM
dpc-5320	40	34	]	]	PUNCT
dpc-5320	40	35	.	.	PUNCT
dpc-5320	41	1	conclusion	conclusion	NOUN
dpc-5320	41	2	we	we	PRON
dpc-5320	41	3	present	present	VERB
dpc-5320	41	4	two	two	NUM
dpc-5320	41	5	cases	case	NOUN
dpc-5320	41	6	of	of	ADP
dpc-5320	41	7	dili	dili	NOUN
dpc-5320	41	8	associated	associate	VERB
dpc-5320	41	9	with	with	ADP
dpc-5320	41	10	adalimumab	adalimumab	NOUN
dpc-5320	41	11	in	in	ADP
dpc-5320	41	12	patients	patient	NOUN
dpc-5320	41	13	with	with	ADP
dpc-5320	41	14	hs	hs	PROPN
dpc-5320	41	15	,	,	PUNCT
dpc-5320	41	16	an	an	DET
dpc-5320	41	17	occurrence	occurrence	NOUN
dpc-5320	41	18	not	not	PART
dpc-5320	41	19	previously	previously	ADV
dpc-5320	41	20	described	describe	VERB
dpc-5320	41	21	in	in	ADP
dpc-5320	41	22	the	the	DET
dpc-5320	41	23	literature	literature	NOUN
dpc-5320	41	24	.	.	PUNCT
dpc-5320	42	1	while	while	SCONJ
dpc-5320	42	2	adalimumab	adalimumab	NOUN
dpc-5320	42	3	remains	remain	VERB
dpc-5320	42	4	a	a	DET
dpc-5320	42	5	cornerstone	cornerstone	NOUN
dpc-5320	42	6	of	of	ADP
dpc-5320	42	7	hs	hs	PROPN
dpc-5320	42	8	treatment	treatment	PROPN
dpc-5320	42	9	,	,	PUNCT
dpc-5320	42	10	these	these	DET
dpc-5320	42	11	cases	case	NOUN
dpc-5320	42	12	underscore	underscore	VERB
dpc-5320	42	13	the	the	DET
dpc-5320	42	14	need	need	NOUN
dpc-5320	42	15	for	for	ADP
dpc-5320	42	16	routine	routine	ADJ
dpc-5320	42	17	hepatic	hepatic	ADJ
dpc-5320	42	18	monitoring	monitoring	NOUN
dpc-5320	42	19	,	,	PUNCT
dpc-5320	42	20	especially	especially	ADV
dpc-5320	42	21	at	at	ADP
dpc-5320	42	22	early	early	ADJ
dpc-5320	42	23	stages	stage	NOUN
dpc-5320	42	24	of	of	ADP
dpc-5320	42	25	therapy	therapy	NOUN
dpc-5320	42	26	.	.	PUNCT
dpc-5320	43	1	clinicians	clinician	NOUN
dpc-5320	43	2	should	should	AUX
dpc-5320	43	3	be	be	AUX
dpc-5320	43	4	aware	aware	ADJ
dpc-5320	43	5	of	of	ADP
dpc-5320	43	6	the	the	DET
dpc-5320	43	7	possibility	possibility	NOUN
dpc-5320	43	8	of	of	ADP
dpc-5320	43	9	severe	severe	ADJ
dpc-5320	43	10	hepatotoxicity	hepatotoxicity	NOUN
dpc-5320	43	11	and	and	CCONJ
dpc-5320	43	12	act	act	VERB
dpc-5320	43	13	promptly	promptly	ADV
dpc-5320	43	14	when	when	SCONJ
dpc-5320	43	15	clinical	clinical	ADJ
dpc-5320	43	16	or	or	CCONJ
dpc-5320	43	17	biochemical	biochemical	ADJ
dpc-5320	43	18	abnormalities	abnormality	NOUN
dpc-5320	43	19	appear	appear	VERB
dpc-5320	43	20	.	.	PUNCT
dpc-5320	44	1	further	further	ADJ
dpc-5320	44	2	research	research	NOUN
dpc-5320	44	3	is	be	AUX
dpc-5320	44	4	needed	need	VERB
dpc-5320	44	5	to	to	PART
dpc-5320	44	6	better	well	ADV
dpc-5320	44	7	understand	understand	VERB
dpc-5320	44	8	the	the	DET
dpc-5320	44	9	risk	risk	NOUN
dpc-5320	44	10	factors	factor	NOUN
dpc-5320	44	11	and	and	CCONJ
dpc-5320	44	12	mechanisms	mechanism	NOUN
dpc-5320	44	13	of	of	ADP
dpc-5320	44	14	adalimumab	adalimumab	NOUN
dpc-5320	44	15	-	-	PUNCT
dpc-5320	44	16	induced	induce	VERB
dpc-5320	44	17	liver	liver	NOUN
dpc-5320	44	18	injury	injury	NOUN
dpc-5320	44	19	,	,	PUNCT
dpc-5320	44	20	ensuring	ensure	VERB
dpc-5320	44	21	safer	safe	ADJ
dpc-5320	44	22	use	use	NOUN
dpc-5320	44	23	of	of	ADP
dpc-5320	44	24	this	this	DET
dpc-5320	44	25	treatment	treatment	NOUN
dpc-5320	44	26	.	.	PUNCT
dpc-5320	45	1	references	reference	NOUN
dpc-5320	45	2	1	1	NUM
dpc-5320	45	3	.	.	PUNCT
dpc-5320	45	4	frider	frider	PROPN
dpc-5320	45	5	b	b	PROPN
dpc-5320	45	6	,	,	PUNCT
dpc-5320	45	7	bruno	bruno	PROPN
dpc-5320	45	8	a	a	X
dpc-5320	45	9	,	,	PUNCT
dpc-5320	45	10	ponte	ponte	PROPN
dpc-5320	45	11	m	m	PROPN
dpc-5320	45	12	,	,	PUNCT
dpc-5320	45	13	amante	amante	PROPN
dpc-5320	45	14	m.	m.	PROPN
dpc-5320	45	15	drug	drug	NOUN
dpc-5320	45	16	-	-	PUNCT
dpc-5320	45	17	induced	induce	VERB
dpc-5320	45	18	liver	liver	NOUN
dpc-5320	45	19	injury	injury	NOUN
dpc-5320	45	20	caused	cause	VERB
dpc-5320	45	21	by	by	ADP
dpc-5320	45	22	adalimumab	adalimumab	NOUN
dpc-5320	45	23	:	:	PUNCT
dpc-5320	45	24	a	a	DET
dpc-5320	45	25	case	case	NOUN
dpc-5320	45	26	report	report	NOUN
dpc-5320	45	27	and	and	CCONJ
dpc-5320	45	28	review	review	NOUN
dpc-5320	45	29	of	of	ADP
dpc-5320	45	30	the	the	DET
dpc-5320	45	31	bibliography	bibliography	NOUN
dpc-5320	45	32	.	.	PUNCT
dpc-5320	46	1	case	case	NOUN
dpc-5320	46	2	reports	report	VERB
dpc-5320	46	3	hepatol	hepatol	ADJ
dpc-5320	46	4	.	.	PUNCT
dpc-5320	47	1	2013;2013:406901	2013;2013:406901	NUM
dpc-5320	47	2	.	.	PUNCT
dpc-5320	48	1	doi:10.1155/2013/406901	doi:10.1155/2013/406901	PROPN
dpc-5320	48	2	.	.	PUNCT
dpc-5320	49	1	pmid	pmid	NOUN
dpc-5320	49	2	:	:	PUNCT
dpc-5320	49	3	25431703	25431703	NUM
dpc-5320	49	4	.	.	PUNCT
dpc-5320	50	1	2	2	NUM
dpc-5320	50	2	.	.	X
dpc-5320	50	3	kok	kok	PROPN
dpc-5320	50	4	b	b	PROPN
dpc-5320	50	5	,	,	PUNCT
dpc-5320	50	6	lester	lester	PROPN
dpc-5320	50	7	elw	elw	PROPN
dpc-5320	50	8	,	,	PUNCT
dpc-5320	50	9	lee	lee	PROPN
dpc-5320	50	10	wm	wm	PROPN
dpc-5320	50	11	,	,	PUNCT
dpc-5320	50	12	et	et	PROPN
dpc-5320	50	13	al	al	PROPN
dpc-5320	50	14	.	.	PROPN
dpc-5320	50	15	acute	acute	ADJ
dpc-5320	50	16	liver	liver	NOUN
dpc-5320	50	17	failure	failure	NOUN
dpc-5320	50	18	from	from	ADP
dpc-5320	50	19	tumor	tumor	NOUN
dpc-5320	50	20	necrosis	necrosis	NOUN
dpc-5320	50	21	factor	factor	NOUN
dpc-5320	50	22	-	-	PUNCT
dpc-5320	50	23	α	α	NOUN
dpc-5320	50	24	antagonists	antagonist	NOUN
dpc-5320	50	25	:	:	PUNCT
dpc-5320	50	26	report	report	NOUN
dpc-5320	50	27	of	of	ADP
dpc-5320	50	28	four	four	NUM
dpc-5320	50	29	cases	case	NOUN
dpc-5320	50	30	and	and	CCONJ
dpc-5320	50	31	literature	literature	NOUN
dpc-5320	50	32	review	review	PROPN
dpc-5320	50	33	.	.	PUNCT
dpc-5320	51	1	dig	dig	VERB
dpc-5320	51	2	dis	dis	PROPN
dpc-5320	51	3	sci	sci	PROPN
dpc-5320	51	4	.	.	PUNCT
dpc-5320	52	1	2018;63(6):1654	2018;63(6):1654	PROPN
dpc-5320	52	2	-	-	SYM
dpc-5320	52	3	1666	1666	NUM
dpc-5320	52	4	.	.	PUNCT
dpc-5320	53	1	doi:10.1007	doi:10.1007	PROPN
dpc-5320	53	2	/	/	SYM
dpc-5320	53	3	s10620	s10620	PROPN
dpc-5320	53	4	-	-	PUNCT
dpc-5320	53	5	018	018	NUM
dpc-5320	53	6	-	-	PUNCT
dpc-5320	53	7	5023	5023	NUM
dpc-5320	53	8	-	-	SYM
dpc-5320	53	9	6	6	NUM
dpc-5320	53	10	.	.	PUNCT
dpc-5320	54	1	pmid	pmid	NOUN
dpc-5320	54	2	:	:	PUNCT
dpc-5320	54	3	29564668	29564668	NUM
dpc-5320	54	4	.	.	PUNCT
dpc-5320	55	1	3	3	X
dpc-5320	55	2	.	.	X
dpc-5320	55	3	french	french	PROPN
dpc-5320	55	4	jb	jb	PROPN
dpc-5320	55	5	,	,	PUNCT
dpc-5320	55	6	bonacini	bonacini	PROPN
dpc-5320	55	7	m	m	PROPN
dpc-5320	55	8	,	,	PUNCT
dpc-5320	55	9	ghabril	ghabril	PROPN
dpc-5320	55	10	m	m	PROPN
dpc-5320	55	11	,	,	PUNCT
dpc-5320	55	12	foureau	foureau	ADJ
dpc-5320	55	13	d	d	NOUN
dpc-5320	55	14	,	,	PUNCT
dpc-5320	55	15	bonkovsky	bonkovsky	PROPN
dpc-5320	55	16	hl	hl	NOUN
dpc-5320	55	17	.	.	PUNCT
dpc-5320	56	1	hepatotoxicity	hepatotoxicity	NOUN
dpc-5320	56	2	associated	associate	VERB
dpc-5320	56	3	with	with	ADP
dpc-5320	56	4	the	the	DET
dpc-5320	56	5	use	use	NOUN
dpc-5320	56	6	of	of	ADP
dpc-5320	56	7	anti	anti	ADJ
dpc-5320	56	8	-	-	ADJ
dpc-5320	56	9	tnf	tnf	ADJ
dpc-5320	56	10	-	-	PUNCT
dpc-5320	56	11	α	α	NOUN
dpc-5320	56	12	agents	agent	NOUN
dpc-5320	56	13	.	.	PUNCT
dpc-5320	57	1	drug	drug	PROPN
dpc-5320	57	2	saf	saf	PROPN
dpc-5320	57	3	.	.	PUNCT
dpc-5320	58	1	2016;39(3):199	2016;39(3):199	NOUN
dpc-5320	58	2	-	-	PUNCT
dpc-5320	58	3	208	208	NUM
dpc-5320	58	4	.	.	PUNCT
dpc-5320	59	1	doi:10.1007	doi:10.1007	VERB
dpc-5320	59	2	/	/	SYM
dpc-5320	59	3	s40264	s40264	NOUN
dpc-5320	59	4	-	-	NOUN
dpc-5320	59	5	0150366	0150366	NUM
dpc-5320	59	6	-	-	PUNCT
dpc-5320	59	7	9	9	NUM
dpc-5320	59	8	.	.	PUNCT
dpc-5320	60	1	pmid	pmid	NOUN
dpc-5320	60	2	:	:	PUNCT
dpc-5320	60	3	26692395	26692395	NUM